Journal
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 34, Issue 3, Pages 789-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2008.05.003
Keywords
-
Categories
Funding
- AstraZeneca
- Donjoy
- Lilly
- Merck
- National Institutes of Health
- Pfizer
- Stryker
- Wyeth
Ask authors/readers for more resources
This article describes what structure modification is, explains the distinctions among preventing, retarding, stopping, and reversing disease, and Suggests approaches that might be clinically meaningful. It discusses whether ally evidence suggests it is possible to modify disease and whether the current focus oil cartilage is appropriate. It considers the methodologic approaches and the obstacles to demonstrating efficacy of these agents in clinical trials. The authors hope that at the end of this narrative review the reader will appreciate the complexities of this rapidly evolving field and of the development of disease-modifying drugs for osteoarthritis drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available